Search company, investor...



Acquired | Acquired

Total Raised




About PercuSurge

PercuSurge pioneered a new market segment in interventional cardiology products with a series of balloon catheters designed to trap and remove the potentially harmful debris that breaks loose during balloon angioplasty and stent placement procedures.

Headquarters Location

Sunnyvale, California, 55432,

United States

Missing: PercuSurge's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PercuSurge's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest PercuSurge News

Medtronic to acquire PercuSurge for $225 million

Jul 21, 2017

In a move that will further enhance its interventional vascular product offerings, Medtronic Inc. (Minneapolis) today announced that it will acquire Sunnyvale, CA-based PercuSurge Inc. The merger agreement calls for an exchange of stock valued at approximately $225 million. Further financial details were not disclosed. PercuSurge will join the Medtronic Vascular organization, which is headquartered in Santa Rosa, CA. "We are excited to be joined by this innovative company, whose embolic protection device is the 'best in class' solution for reducing clinical complications associated with embolic debris released during interventional procedures," said Andy Rasdal, president of Medtronic Vascular. "We believe that our technology and excellent clinical results, combined with Medtronic AVE's worldwide operational and field infrastructure will result in an extremely rapid adoption of our technology to treat the nearly 200,000 diseased saphenous vein bypass grafts that could be treated each year," said Peter Rule, president, CEO and chairman of PercuSurge. The PercuSurge GuardWire Plus Temporary Occlusion and Aspiration system is designed to allow cardiologists and other interventional specialists to capture embolic debris that might otherwise block downstream vessels and branches during interventional procedures and damage the heart. It consists of a balloon-tipped guidewire, which is inflated briefly to occlude blood flow and capture any material dislodged from the wall of the vessel during placement of a stent upstream. Captured material is then withdrawn by using the PercuSurge Export aspiration catheter before the balloon of the GuardWire Plus is deflated and blood flow restored. The device has been used in over 5,000 procedures since its release in Europe during 1999 and was the first distal protection product to be commercialized there. The product's first targeted indication is for the treatment of degenerated saphenous vein grafts that show signs of disease following heart bypass surgery. The GuardWire Plus is an investigational device in the United States, and clinical trials are already underway. Edited by Ursula Jones

PercuSurge Frequently Asked Questions (FAQ)

  • Where is PercuSurge's headquarters?

    PercuSurge's headquarters is located at Sunnyvale.

  • What is PercuSurge's latest funding round?

    PercuSurge's latest funding round is Acquired.

  • How much did PercuSurge raise?

    PercuSurge raised a total of $58.2M.

  • Who are the investors of PercuSurge?

    Investors of PercuSurge include Medtronic, InterWest Partners, MedVenture Associates, BioVentures Investors, Montreux Equity Partners and 3 more.

  • Who are PercuSurge's competitors?

    Competitors of PercuSurge include SetPoint Medical, PulmonX, Prometheus Laboratories, SmartPill Corporation, Micronics Microfluidics and 11 more.

Compare PercuSurge to Competitors

Vitreo Retinal Technologies

Vitreo Retinal Technologies, Inc. is developing therapeutics for the treatment of serious ocular diseases.

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders


Zeno Corporation is a Houston-based medical technology company engaged in the development of products using its patented ClearPoint technologyˆ as well as other products related to skin care.

SetPoint Medical Logo
SetPoint Medical

SetPoint Medical develops a bioelectronic medicine platform using a small implanted device that activates the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The company was founded in 2006 and is based in Santa Clarita, California.


MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

Dialysis Systems

Dialysis Systems Inc., based in Nashville, Tennessee, designs, manufactures and markets fluid purification, treatment and delivery systems for dialysis clinics and other medical facilities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.